AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis

RecruitingPhase 1Ages 18 Years - 45 YearsAllNantes University Hospital
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The etiologic mechanisms involved in multiple sclerosis (MS) are not yet fully understood. Indeed MS is a multifactorial disease involving genetic and environmental factors and Epstein-Barr-Virus (EBV) could be one of these factors. However the link between EBV infection and the immunological mechanisms underlying MS is not clear. Robust sero-epidemiological evidences support an association between EBV infection and MS, and immunological data suggest an altered/deficient immune response against this virus. In healthy individuals EBV produces a persistent infection that is tightly controlled by the immune system. In patients with MS, cellular and humoral immune studies demonstrate an altered response against the virus with a T-cell abnormal reactivity against the EBV-infected autologous B-cells, elevated humoral immune response to Epstein Barr Nuclear Antigen-1, and in the case of childre

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * 18\<Ageโ‰ค45 years * Patients with : * A clinically isolated syndrome (first acute or sub acute neurological event consistent with demyelination \[i.e. optic neuritis, spinal cord syndrome, brainstem/ cerebellar syndrome\]) * And a MRI scan showing dissemination of MRI lesions in space based on 2017 McDonald criteria At least 1 lesion detected in 2 or more following locations (sites) periventricular, cortical or juxtacortical, infratentorial, spinal cord * With a possible dissemination in time based on the revised McDonald cirteria and evicenced on simultaneous detection of one Gadolinium (Gd) enhancing and non-Gd enhancing lesions * Or demonstration of CSF-specific oligoclonal bands (OCBs) * EDSS Score \<3 * Patients covered by health care insurance (social security) * Written informed consent obtained. * Onset of symptoms occurring within 60 days of inclusion * Patients with HIV, HTLV, Hepatitis B, C Syphilis testing negative within 30 days * Positive EBV serology * White blood cell count (Leukocytes) \> 750/mm3 * Negative pregnancy test Exclusion Criteria: * Patients with clinically definite multiple sclerosis * Patients known to have HIV, HTLV Hepatitis A, B, C or Syphilis infections or patient with active uncontrolled systemic bacterial, viral, parasitic or fungal infections. * Patients with white blood cell count (Leukocytes) \< 750/mm3 * Pregnant or breast feeding women * Patient with childbearing potentiel refusing efficient contraceptive method * Patients wishing to be pregnant during the course of the study * Patients under legal guardianship * Concomitant participation of any other trial * Patients with mental or psychiatry condition unable to understand the trial * Patients with any medically unstable condition or any health conditions that may impact the safety of the patient as determined by the investigator or patient with any stable condition treated with immunotherapy * Patients with a history of cancer within 5 years or progressive cancer except for basal or cell skin lesions surgically excised and cured, in situ cervical cancer * Patients unable to comply with protocol. * Contraindication for MRI or/and any known history of hypersensitivity to contrast medium * Patients currently treated with immunosuppressive drugs including oral or systemic corticosteroids
๐Ÿ’Š

What it tests

  • Cellular therapy with EBV specific autologous CTL infusion
๐Ÿ“

Where

1 site
University Hospital
Nantes, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy